Login / Signup

Aging restricts the ability of mesenchymal stem cells to promote the generation of oligodendrocytes during remyelination.

Francisco J RiveraAlerie Guzman de la FuenteChao ZhaoMaria Elena SilvaGinez A GonzalezRoman WodnarMartina FeichtnerSimona LangeOihana ErreaEleni PriglingerAnna O'SullivanPasquale RomanelliJanusz J JadaszGabriele BrachtlRichard GreilHerbert TempferAndreas TrawegerLuis Federico BatizPatrick KürySebastien Couillard-DespresRobin J M FranklinLudwig Aigner
Published in: Glia (2019)
Multiple sclerosis (MS) is a demyelinating disease of the central nervous system (CNS) that leads to severe neurological deficits. Due to their immunomodulatory and neuroprotective activities and their ability to promote the generation of oligodendrocytes, mesenchymal stem cells (MSCs) are currently being developed for autologous cell therapy in MS. As aging reduces the regenerative capacity of all tissues, it is of relevance to investigate whether MSCs retain their pro-oligodendrogenic activity with increasing age. We demonstrate that MSCs derived from aged rats have a reduced capacity to induce oligodendrocyte differentiation of adult CNS stem/progenitor cells. Aging also abolished the ability of MSCs to enhance the generation of myelin-like sheaths in demyelinated cerebellar slice cultures. Finally, in a rat model for CNS demyelination, aging suppressed the capability of systemically transplanted MSCs to boost oligodendrocyte progenitor cell (OPC) differentiation during remyelination. Thus, aging restricts the ability of MSCs to support the generation of oligodendrocytes and consequently inhibits their capacity to enhance the generation of myelin-like sheaths. These findings may impact on the design of therapies using autologous MSCs in older MS patients.
Keyphrases